CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

CytomX shares jumped 44% after phase I data for Varseta-M in heavily pretreated metastatic colorectal cancer showed rising response rates and strong disease control. The positive early clinical readout triggered a large single-day move and increased investor optimism, though the data are preliminary and will require confirmation in later-stage trials.

Analysis

CytomX shares jumped 44% after phase I data for Varseta-M in heavily pretreated metastatic colorectal cancer showed rising response rates and strong disease control. The positive early clinical readout triggered a large single-day move and increased investor optimism, though the data are preliminary and will require confirmation in later-stage trials.